🏛️ Verified NIH Record • Updated 2026-03-31
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (NCT03762850)
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Travere Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Who can join: Review the eligibility criteria below.
Location: Travere Investigational Site — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (162 Sites)
Showing the first 25 of 162 sites.
- Travere Investigational Site — Birmingham, Alabama
- Travere Investigational Site — Homewood, Alabama
- Travere Investigational Site — Glendale, California
- Travere Investigational Site — Montebello, California
- Travere Investigational Site — Northridge, California
- Travere Investigational Site — San Diego, California
- Travere Investigational Site — San Diego, California
- Travere Investigational Site — Stanford, California
- Travere Investigational Site — Denver, Colorado
- Travere Investigational Site — Coral Springs, Florida
- Travere Investigational Site — Hollywood, Florida
- Travere Investigational Site — Miami, Florida
- Travere Investigational Site — Miami, Florida
- Travere Investigational Site — Winter Park, Florida
- Travere Investigational Site — Lawrenceville, Georgia
- Travere Investigational Site — Nampa, Idaho
- Travere Investigational Site — Hinsdale, Illinois
- Travere Investigational Site — Muncie, Indiana
- Travere Investigational Site — Kansas City, Kansas
- Travere Investigational Site — Louisville, Kentucky
- Travere Investigational Site — Boston, Massachusetts
- Travere Investigational Site — Springfield, Massachusetts
- Travere Investigational Site — Worcester, Massachusetts
- Travere Investigational Site — Minneapolis, Minnesota
- Travere Investigational Site — Reno, Nevada
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: Following completion of the visit 12 weeks after the OLE baseline visit, eligible patients may receive open-label dapagliflozin for at least 12 weeks but up to 24 additional weeks, or through the e...
More studies in Immunoglobulin A Nephropathy
- A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US — Boston, Massachusetts
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — Birmingham, Alabama
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Alabaster, Alabama
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Huntsville, Alabama
Explore by condition: All Immunoglobulin A Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.